Translational medicine: mitigating risks for investigators.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Translational medicine: An effective approach to improve healthcare by research and innovation in developing countries.Medicine · 2025
   Review
2. Translational research in biomedical sciences in India: Challenges, observations & national perspectives.The Indian journal of medical research · 2020
   Article
3. Awareness of and attitudes toward translational medicine among health personnel in hospitals in Shanghai, China.The Journal of international medical research · 2019
   Article
4. The oxidative stress theory of disease: levels of evidence and epistemological aspects.British journal of pharmacology · 2017
   Review
5. A new cell-penetrating peptide that blocks the autoinhibitory XIP domain of NCX1 and enhances antiporter activity.Molecular therapy : the journal of the American Society of Gene Therapy · 2015
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as